Comparative Characterisation of Five Plasma-Derived Human Serum Albumin Preparations: Structural Integrity, Functional Properties, and Quality Attributes
VIALEBEX® demonstrated greater structural integrity and functional properties despite a higher polymer content, suggesting complex quality relationships beyond simple aggregation.
Abstract
Background: Human serum albumin (HSA) is a critical therapeutic protein with widespread clinical applications. Despite standardised manufacturing protocols, quality variations between HSA preparations are poorly characterised. Objective: To comprehensively characterise five commercial plasma-derived albumin preparations (VIALEBEX®, ALBUNORM®, ALBUREX®, FLEXBUMIN®, ALBUTEIN®) using multiple analytical approaches to assess structural integrity, post-translational modifications, functional properties and purity. Methods: Ten batches in total from five manufacturers were analysed using size-exclusion chromatography (SEC) for aggregate quantification, ion exchange chromatography (IEX) for isoform profiling, surface plasmon resonance (SPR) for neonatal Fc receptor (FcRn) binding, and liquid chromatography-tandem mass spectrometry (LC-MS/MS) for protein quantification. Results: VIALEBEX® contained the highest proportion of native HSA (35.2% vs. 15.1–22.2%) and the lowest levels of oxidised forms (13.2% vs. 27.4–33.3%) despite higher polymer content. SPR demonstrated higher FcRn binding affinity for VIALEBEX®. All preparations exceeded 98% albumin purity, with varying co-purified protein profiles. Conclusions: Significant quality variations exist between HSA preparations. VIALEBEX® demonstrated greater structural integrity and functional properties despite a higher polymer content, suggesting complex quality relationships beyond simple aggregation. The preservation of structural integrity and higher redox state of VIALEBEX® could be relevant considerations when selecting a product for clinical or pre-clinical use.
This review summarizes the current understanding of PTMs affecting human serum albumin, with particular emphasis on their molecular origins and functional implications, and examines established and emerging applications of PTM-modified albumin in diagnostics, critical care, extracorporeal detoxification, drug delivery,...
Roko Gladović, João G. Brás, J. Vollenbroek et al.· Toxins· 0 citations
Background. By-products of human donor plasma fractionation often possess untapped potential for regenerative medicine. However, they are frequently excluded from further technological processing, and a comprehensive physicochemical and biological characterization remains lacking – a gap that hinders the development of...
D. Alekseev, L. Volova, N. A. Ryabov et al.· Science and Innovations in M...· 0 citations
A generalizable approach for identifying molecular differences between endogenous and recombinant proteins and leveraging these features to develop high-quality bioanalytical assays is outlined.
Alexander Schäfer, Paulina Dabrowska-Schlepp, Andreas Busch et al.· Bioanalysis· 0 citations
Plasma protein binding (PPB) is a critical determinant of drug pharmacokinetics, as only the unbound fraction (fᵤ) of a drug is available for tissue distribution, target engagement, and clearance. However, the interaction of rebastinib with plasma proteins has not been fully elucidated to date. In this study, the free...
Suryakant Kumar, B. Bhushan, Bhumika Sharma et al.· Toxicology International· 0 citations
Advanced structural characterization incorporates ultra-high-performance liquid chromatography, size-exclusion chromatography, and native high-resolution mass spectrometry across intact, middle-down, and top-down methods to resolve size variants, charge distribution profiles, disulfide linkages, and critical quality at...
Phanisai Yeminedi, Murali Karthik Jalla, Bhavya Sri Kakarla et al.· Journal of Pharma Insights a...· 0 citations
Ubiquitin C-terminal hydrolase L1 (UCH-L1) is a clinically utilized biomarker of neuronal injury, including traumatic brain injury. Broader implementation of UCH-L1 testing across immunoassay platforms requires well-characterized recombinant materials to support assay linearity verification, internal quality cont...